Modulation Therapeutics logo

Information Links

    Modulation Therapeutics Receives Seed Funding through Florida Institute.                                                                                                                                                                                                                                                            Tampa-Based Company is Eleventh to Receive Capital through the SCAP Program 
                                                                                                                                                                                                                                                                                                                                                                                                 Multiple Myeloma Research Foundation (MMRF) Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment.                                                                                                                                                                                                                                                                                        MMRF Biotech Investment Award Bolsters Development of Novel Myeloma Therapies.



    MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in Multiple Myeloma.

    Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.                Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18. PubMed PMID: 24048737; PubMed Central PMCID: PMC3859963.


    Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype.

    Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.                                        Mol Cancer Ther. 2011 Dec;10(12):2257-66. Epub 2011 Oct 6. PubMed PMID: 21980133;                       PubMed Central PMCID: PMC3237739.


    HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.

    Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA.                  Mol Cancer Ther. 2009 Aug;8(8):2441-51. Epub 2009 Aug 11. PubMed PMID: 19671765;                     PubMed Central PMCID: PMC2761715.


    Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5.

    Sroka TC, Pennington ME, Cress AE.       Carcinogenesis. 2006 Sep;27(9):1748-57. Epub 2006 Mar 14. PubMed PMID: 16537560

Latest News

  • Modulation Therapeutics is awarded STTR Phase I grant to develop Peptoid-Peptide library. June 30th, 2014

  • Modulation Therapeutics is awarded 3rd SBIR Phase I grant in collaboration with Cristoph Radar and the Scripps Research Institute, Scripps Florida. Aug. 1st, 2013

  • Modulation Therapeutics receives seed funding through Florida Institute. Feb. 14th, 2013
  • Modulation Therapeutics is awarded 2nd SBIR Phase I   grant to determine the role of  MTI-101 treatment in modulating the bone marrow niche. Oct. 25th, 2012

  • Modulation Therapeutics is awarded a Phase I SBIR grant to evaluate PK of MT-101 and analogs of MTI-101. Sept. 10th, 2012

  • Modulation Therapeutics in collaboration with Moffitt Cancer Center is awarded a Bankhead Coley grant for preclinical testing of MTI-101 in Acute Myeloid Leukemia. June 2012

  • Multiple Myeloma Research Foundation (MMRF) Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment. June 2012

  • Modulation Therapeutics establishes research facilities at USF Connect research park Jan. 2012

  • Modulation Therapeutics awarded James and Esther King grant. Dec. 2011